Nutralife Melatonin
Natural health product licensed in Canada
- Licence holder
- Easten Light Enterprise Ltd
- NPN or DIN-HM
- 80046519
- Status
- Active licence
- Licence date
- 26 November 2013
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Sublinguale
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]acétamide Source : Mélatonine | 5 mg |
Non-medicinal ingredients
D-Mannitol, Croscarmellose de sodium, Sorbitol, Stéarate de magnésium, Xylitol, Dioxyde de silicium colloïdal
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Helps increase the total sleep time in people suffering from sleep restriction or altered sleep schedule, e.g. shift-work and jet lag. Helps re-set the body's sleep-wake cycle. Helps to prevent and/or reduce the effects of jet lag (e.g. daytime fatigue, sleep disturbance) for people travelling by plane easterly across two or more time zones.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
If you are pregnant or breastfeeding, do not use this product.
- Précautions et mises en garde
Consumption with alcohol, other medications or natural health products with sedative properties is not recommended. If you are taking one of the following medications, consult a health care practitioner prior to use: anticoagulant, anticonvulsant, blood pressure medications, immunosuppressive medications, sedative, hypnotic or psychotropic medications, or steroids. If you have one of the following conditions, consult a health care practitioner prior to use: asthma, cardiovascular disease, chronic kidney disease, depression, diabetes or hypoglycaemia, hormonal disorder, immune system disease, liver disease, migraine, or seizure disorders. If symptoms persist continuously for more than 4 weeks (chronic insomnia), consult your health care practitioner.
Source
Official Health Canada record, licence 80046519
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.